Data from 68 patients (target of 324) on the paxalisib-ONC201 combo shows mOS of 16.5 months vs. 9-12 months in historical control:
https://academic.oup.com/neuro-oncology/article-abstract/25/Supplement_5/v97/7405821?redirectedFrom=fulltext
Further evidence on this treatment combination outside of the PNOC trial with even more impressive mOS results:
https://academic.oup.com/neuro-oncology/article-abstract/25/Supplement_5/v232/7406650
- Forums
- ASX - By Stock
- Excellent interim DIPG data from PNOC
Data from 68 patients (target of 324) on the paxalisib-ONC201...
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online